Astrazeneca PLC Sponsored ADR (AZN.US) announces positive results from the FLAURA2 study, showing that the combination therapy with osimertinib improves overall survival in lung cancer.

On July 21st, Astrazeneca PLC Sponsored ADR (AZN.US) announced that the final overall survival (OS) analysis of the phase III FLAURA2 study yielded positive results: in patients with locally advanced or metastatic epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NSCLC) receiving first-line treatment, osimertinib in combination with pemetrexed and platinum-based chemotherapy showed statistically significant and clinically meaningful improvement in the key secondary endpoint OS compared to osimertinib monotherapy. The final OS analysis results were consistent with the mid-term OS results reported earlier, confirming sustained survival benefit and building on the previously published primary endpoint data - which demonstrated the longest reported median progression-free survival (PFS) in this treatment setting. Pasi A. Jnne, the principal investigator of the FLAURA2 trial, stated: "The goal of treating lung cancer is to both prolong survival and improve patient experience, especially in first-line treatment where the treatment duration may be long and many patients still need to maintain an active lifestyle. These positive results support osimertinib (whether as monotherapy or in combination with chemotherapy) as the standard treatment regimen for patients with advanced EGFR-mutant lung cancer in the first-line setting, and reinforce the significant benefits of this combination therapy in the current clinical environment. The observed survival benefit, particularly considering the lack of restrictions on subsequent treatment choices following disease progression in the FLAURA2 trial, is particularly impressive."